{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:06:07Z","timestamp":1786125967622,"version":"build-2736575974"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012443","name":"Maryland Stem Cell Research Fund","doi-asserted-by":"publisher","award":["2023-MSCRFD-6101"],"award-info":[{"award-number":["2023-MSCRFD-6101"]}],"id":[{"id":"10.13039\/100012443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012443","name":"Maryland Stem Cell Research Fund","doi-asserted-by":"publisher","award":["2025-R2-MSCRFD-00008"],"award-info":[{"award-number":["2025-R2-MSCRFD-00008"]}],"id":[{"id":"10.13039\/100012443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["PC200110"],"award-info":[{"award-number":["PC200110"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}]},{"name":"Giant Food","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Epidermal Growth Factor Receptor (EGFR) is often present on the cell surface of a wide variety human malignancies, including non-small-cell lung cancer (NSCLC), glioblastoma (GBM), pancreatic ductal carcinoma (PDC), and castration-resistant prostate cancer (CRPC). Efforts to optimize immunotherapies targeting EGFR are limited by murine intolerance of human EGFR. To overcome this obstacle, we developed C57BL\/6 mice in which a truncated variant of human EGFR (hEGFRt), lacking the ligand binding domain and cytoplasmic domain, is expressed from the CAG regulatory elements comprised of the CMV enhancer, \u03b2-actin promoter, and \u03b2-globin poly-adenylation signals. Cetuximab, a high-affinity, clinically available anti-human EGFR antibody, retains affinity for hEGFRt. The hEGFRt cDNA in the CAG-hEGFRt transgene is flanked by\n                    <jats:italic>lox<\/jats:italic>\n                    P sites to enable its excision thereby reducing interaction of hEGFRt-directed immunotherapies with normal tissues. The CAG-hEGFRt(f\/f) transgene is abundantly expressed in hematopoietic lymphoid and myeloid cells, with low-level expression evident also in non-hematopoietic liver, lung, kidney, and brain. Mx1-Cre-mediated transgene excision in adult mice reduces hEGFRt\u2009~\u20095-fold in blood mononuclear cells. CAG-hEGFRt(f\/f) adult mice are tolerant of syngeneic NSCLC, GBM, prostate, and PDC lines expressing hEGFRt. These mice retain hEGFRt tolerance after transgene deletion. CAG-hEGFRt(f\/f) mice provide a new and important tool for the development of immunotherapies targeting hEGFR.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0355841","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:32:46Z","timestamp":1786123966000},"page":"e0355841","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Transgenic mouse tolerant to syngeneic cancer cells expressing truncated human epidermal growth factor receptor"],"prefix":"10.1371","volume":"21","author":[{"given":"Theresa","family":"Barberi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahila","family":"Khuroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-7061","authenticated-orcid":true,"given":"Alan D.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"pone.0355841.ref001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.08.002","article-title":"EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis","volume":"72","author":"F Agustoni","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"pone.0355841.ref002","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/138945012800564158","article-title":"Targeting EGFR in pancreatic cancer treatment","volume":"13","author":"T Troiani","year":"2012","journal-title":"Curr Drug Targets"},{"issue":"4","key":"pone.0355841.ref003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.03.002","article-title":"Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF","volume":"35","author":"MT Blasco","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"pone.0355841.ref004","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"G Di Lorenzo","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"pone.0355841.ref005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2727.163129","article-title":"Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas","volume":"7","author":"AA Changavi","year":"2015","journal-title":"J Lab Physicians"},{"issue":"4","key":"pone.0355841.ref006","first-page":"246","article-title":"Epidermal growth factor receptor as a therapeutic target in colorectal cancer","volume":"2","author":"RB Cohen","year":"2003","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"pone.0355841.ref007","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"CW Brennan","year":"2013","journal-title":"Cell"},{"issue":"1","key":"pone.0355841.ref008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3892\/ol.2017.6221","article-title":"Epidermal growth factor receptor in glioblastoma","volume":"14","author":"H Xu","year":"2017","journal-title":"Oncol Lett"},{"key":"pone.0355841.ref009","doi-asserted-by":"crossref","first-page":"107414","DOI":"10.1016\/j.lungcan.2023.107414","article-title":"Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives","volume":"187","author":"T Kato","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"pone.0355841.ref010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000244","article-title":"NF-\u03baB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma","volume":"8","author":"R Suresh","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"pone.0355841.ref011","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/1878-0261.12904","article-title":"Adoptive transfer of immature myeloid cells lacking NF-\u03baB p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma","volume":"15","author":"C Cui","year":"2021","journal-title":"Mol Oncol"},{"key":"pone.0355841.ref012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00262-024-03939-4","article-title":"PSMA antibody, humanized PSMA.CAR10.3, or cetuximab increases prostate cancer localization of NF-\u03baB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny","volume":"74","author":"MA Alzubi","year":"2025","journal-title":"Cancer Immunol Immunoth"},{"issue":"15","key":"pone.0355841.ref013","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.18632\/oncotarget.24242","article-title":"Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab","volume":"9","author":"X He","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"pone.0355841.ref014","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"X Wang","year":"2011","journal-title":"Blood"},{"issue":"10","key":"pone.0355841.ref015","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-018-2184-2","article-title":"Absence of host NF-\u03baB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization","volume":"67","author":"T Barberi","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"pone.0355841.ref016","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1074\/jbc.M115.674234","article-title":"Runx1 Phosphorylation by Src increases trans-activation via augmented stability, reduced histone deacetylase (HDAC) binding, and increased DNA affinity, and activated Runx1 favors granulopoiesis","volume":"291","author":"WY Leong","year":"2016","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0355841.ref017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining Local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity","volume":"5","author":"Y Leshem","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:32:49Z","timestamp":1786123969000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0355841"}},"subtitle":[],"editor":[{"given":"Junming","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0355841","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}